Amgen Spinoff Atara Biotherapeutics Hikes IPO Target From $50 Million To $92 Million

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Atara Biotherapeutics Inc. supersized its planned IPO to up to $92 million, offering 5.75 million shares at a range of $14 to $16 each.

The Brisbane spinout of Amgen Inc., which counts among its investors legendary Mexican billionaire Carlos Slim, last month eyed a $50 million initial public offering. Now it is the second Bay Area life sciences company this week to raise its IPO target.

Help employers find you! Check out all the jobs and post your resume.

Back to news